| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/30/2005 | CA2495048A1 Hemostatic compositions and devices |
| 07/30/2005 | CA2494431A1 Pharmaceutical hard capsule containing inorganic substance |
| 07/29/2005 | CA2477330A1 Active agent delivery device |
| 07/28/2005 | WO2005068533A1 Boigradable multi-block co-polymers |
| 07/28/2005 | WO2005068498A2 Human therapeutic cells secreting nerve growth factor |
| 07/28/2005 | WO2005068016A1 Dermal patch for iontophoresis |
| 07/28/2005 | WO2005067994A1 Crosslinked hyaluronic acid compositions for tissue augmentation |
| 07/28/2005 | WO2005067977A1 Method of preparation of a fungal glucane hydrogel having antibacterial and immunostimulant activity, and use thereof |
| 07/28/2005 | WO2005067976A2 Direct compression formulation and process |
| 07/28/2005 | WO2005067975A1 Title: a sustained release captopril formulation having a supermolecular intercalation structure and the preparation process thereof |
| 07/28/2005 | WO2005067966A1 Methods for tailoring the immune response to an antigen or immunogen |
| 07/28/2005 | WO2005067943A1 Compostions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug |
| 07/28/2005 | WO2005067941A1 Topical aciclovir formulation |
| 07/28/2005 | WO2005067926A1 Pharmaceutical composition of amlodipine maleate having enhanced stability |
| 07/28/2005 | WO2005067924A1 Use of pilocarpine for hypoptyalism treatment |
| 07/28/2005 | WO2005067910A1 Tulobuterol adhesive patch |
| 07/28/2005 | WO2005067905A1 Propofol-containing fat emulsion preparation |
| 07/28/2005 | WO2005067898A2 Improved sustained release compositions for pulmonary administration of insulin |
| 07/28/2005 | WO2005067897A1 Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid |
| 07/28/2005 | WO2005067896A1 Electrically conductive adhesive hydrogels with a thermally activated chemical initiator |
| 07/28/2005 | WO2005067895A1 Controlled release pharmaceutical compositions |
| 07/28/2005 | WO2005067894A1 Stable beadlets of lipophilic nutrients |
| 07/28/2005 | WO2005067893A2 Pharmaceutical compositions comprising midazolam in a high concentration |
| 07/28/2005 | WO2005067892A1 Lipid compositions and methods of use |
| 07/28/2005 | WO2005067891A1 Compositions comprosing memantine and polyanionic polymers for administration to the eye |
| 07/28/2005 | WO2005067890A2 Controlled release cgrp delivery composition for cardiovascular and renal indications |
| 07/28/2005 | WO2005067889A1 Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh |
| 07/28/2005 | WO2005067887A2 Formulations of ramipril |
| 07/28/2005 | WO2005067865A1 Oral anaesthetic gel |
| 07/28/2005 | WO2005067837A1 Dressing pad |
| 07/28/2005 | WO2005067632A2 Lipid compositions and use thereof |
| 07/28/2005 | WO2005067583A2 Immunoliposome-nucleic acid amplication (ilnaa) assay |
| 07/28/2005 | WO2005067517A2 Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers |
| 07/28/2005 | WO2005067499A2 Method and device for topical delivery of therapeutic agents to the skin |
| 07/28/2005 | WO2005058285B1 Tablets having an emulsified polymer matrix for the controlled emission of gas, and production process |
| 07/28/2005 | WO2005056708A3 Bioadhesive polymers with catechol functionality |
| 07/28/2005 | WO2005055978A3 A method of engineering particles for use in the delivery of drugs via inhalation |
| 07/28/2005 | WO2005053636A3 Cosmetic and dermatological oxygen carrier system |
| 07/28/2005 | WO2005051428A3 Method for obtaining a thermoreversible gel with a controlled three-dimensional structure, and gel obtained |
| 07/28/2005 | WO2005051349A3 Pharmaceutical compositions of mirtazapine |
| 07/28/2005 | WO2005049211A3 Fiber rich fraction of trigonella foenum-graceum seeds and its use as a pharmaceutical excipient |
| 07/28/2005 | WO2005048982A3 Efficient introduction of an aerosol into a ventilator circuit |
| 07/28/2005 | WO2005048965A3 Method and composition for breath freshening |
| 07/28/2005 | WO2005046566A3 Stable gabapentin containing composition |
| 07/28/2005 | WO2005041942A9 Three-dimensional mammalian ovarian follicular cell and ovarian follicle culture systems in a biocompatible matrix |
| 07/28/2005 | WO2005040105B1 Novel surfactants and applications thereof |
| 07/28/2005 | WO2005039481A3 Oral drug delivery system |
| 07/28/2005 | WO2005030935A3 Adjuvant activities of mutants of lt-iia and lt-iib enterotoxin lacking binding to ganglioside |
| 07/28/2005 | WO2005030126A3 Adhesin-specific nanoparticles and process for using same |
| 07/28/2005 | WO2005011647A3 Pharmaceutical composition |
| 07/28/2005 | WO2005007599A3 Hydroxyapatite calcium phosphate granules, method for preparing same and uses thereof |
| 07/28/2005 | WO2005007110A9 Compositions and methods for hydrophobic drug delivery |
| 07/28/2005 | WO2004112724A3 Compositions for and methods for treating hiv |
| 07/28/2005 | WO2004108067A3 Programmed drug delivery system |
| 07/28/2005 | WO2004096173A3 Method for the dispersion of water-soluble or hydrophilic substances in a supercritically pressurized fluid |
| 07/28/2005 | WO2004080381A3 Impregnated powder improving bioavailability and/or solubility and method of production |
| 07/28/2005 | WO2004070994A3 Wireless medical data communication system and method |
| 07/28/2005 | WO2004070556A3 Method and system for integrating data flows |
| 07/28/2005 | WO2004066938A3 Method and composition for lowering cholesterol |
| 07/28/2005 | WO2004064767A3 Nitric oxide inducing agents |
| 07/28/2005 | WO2004043363A8 Protein-stabilized liposomal formulations of pharmaceutical agents |
| 07/28/2005 | WO2004033620A3 Methods and compositions for therapeutic use of rna interference |
| 07/28/2005 | US20050165348 Needleless syringe using supersonic gas flow for particle delivery |
| 07/28/2005 | US20050165245 Transferring drugs; antitumor agents, anticancer agents |
| 07/28/2005 | US20050165244 precipitating the citalopram base in crystalline form, and transforming the base into a pharmaceutically acceptable citalopram salt; useful for removing intermediates which are structurally closely related to citalopram |
| 07/28/2005 | US20050165203 Polyarylates for drug delivery and tissue engineering |
| 07/28/2005 | US20050165188 Water-soluble or water-swellable crosslinked copolymers |
| 07/28/2005 | US20050165128 Responsive biomedical composites |
| 07/28/2005 | US20050165110 Use of treprostinil to improve kidney functions |
| 07/28/2005 | US20050165102 Improved bioavailability by complexing a drug such as metformin with an ionic moiety such as a fatty acid; e.g. metformin laurate; wrong claims attached to this publication |
| 07/28/2005 | US20050165092 Crystalline base of citalopram |
| 07/28/2005 | US20050165091 includes a buffering agent to stabilize and maintain the pH below 9 in an aqueous dispersion; slow the degradation; shelf-life |
| 07/28/2005 | US20050165038 Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects |
| 07/28/2005 | US20050164997 a 3-oxo-androstancarbothioic acid compound; respiaratory system disorder |
| 07/28/2005 | US20050164986 Especially the sulfobutyl ether cyclodextrin, Captisol"; simplified aqueous formulations without conventional preservatives; nontoxic; storage stability and freeze resistance; biostatic and biocidal towards E coli, Pseudomonas aeruginzosa, Stapphylococcus aureus, Candida albicans, and Aspergillus niger |
| 07/28/2005 | US20050164984 Chondroitin synthase gene and methods of making and using same |
| 07/28/2005 | US20050164974 Ligand is covalently linked to polyoxyethylene glycol having specific binding affinity for vascular endothelial growth factor; SELEX method; improved pharmacokinetics |
| 07/28/2005 | US20050164972 Cationic lipids capable of facilitating transport of biologically active agents or substances into cells; lipid aggregate macromolecular complex interacts with cells making the polyanionic macromolecule available for absorption and uptake by the cell |
| 07/28/2005 | US20050164971 Acyclic and macrocyclic, aliphatic diammonium surfactants for use in forming lipid aggregates for drug delivery of macromolecules; improved versatility among different cell types and broadened range of molecules to be carried |
| 07/28/2005 | US20050164964 Mixture of a nucleic acid and a chitosan with branching groups attached to the amino group, selected from alkyl groups with 2 or more carbon atoms, monosaccharides, oligosaccharides or polysaccharides; gene therapy, genetic vaccines, antisense therapy, anticarcinogenic agents, autoimmune diseases |
| 07/28/2005 | US20050164963 Components for producing amphoteric liposomes |
| 07/28/2005 | US20050164948 Methods of treatment with prosaposin-derived peptides |
| 07/28/2005 | US20050164919 Bactericides; peptide antibiotics |
| 07/28/2005 | US20050164916 Glycopeptide phosphonate derivatives |
| 07/28/2005 | US20050164391 Cationic lipids capable of facilitating transport of biologically active agents or substances into cells; lipid aggregate macromolecular complex interacts with cells making the polyanionic macromolecule available for absorption and uptake by the cell |
| 07/28/2005 | US20050164368 Transgenic, grampositive bacteria comprising expression vector coding viricidal agent for use in treatment and prevention of gastrointestinal disorders in infants |
| 07/28/2005 | US20050163878 Therapeutic agent of skin diseases |
| 07/28/2005 | US20050163868 mixtures of plant extracts, cellulose esters, sodium bicarbonate and silica, having improved disintegration and dissolution properties |
| 07/28/2005 | US20050163866 Solid dosage form |
| 07/28/2005 | US20050163864 Comprises vitamin C, vitamin E, vitamin A (beta-carotene), zinc oxide, and cupric oxide; for promotion of retinal health |
| 07/28/2005 | US20050163859 Injectable compositions for the controlled delivery of pharmacologically active compound |
| 07/28/2005 | US20050163858 active agent has a mean particle size greater than 85 micrometers; controlled-release dosage form; compounded with a histamine-2 antagonist |
| 07/28/2005 | US20050163857 Clarithromycin formulations having improved bioavailability |
| 07/28/2005 | US20050163856 Abuse-resistant sustained-release opioid formulation |
| 07/28/2005 | US20050163855 4-Methyl-5-(2-pyrazinyl)-1,2-dithiol-3-thione; solid-dispersing in the polymer and organic solvent or purified water; mixed solution may be spray dried using a spray dryer or granulated using a fluid bed granulator |
| 07/28/2005 | US20050163854 Antimicrobial composites, films, labelstocks and labels |
| 07/28/2005 | US20050163853 Novel biomaterials their preparation and use |
| 07/28/2005 | US20050163852 pre-treatment of cross-linked polymer with pure supercritical fluid to allow higher degree and more rapid kinetic of drug loading and also a higher thermodynamic activation of the drugs; gas-like low viscosities lead to higher rates of flow and diffusion, liquid-like densities permit higher solvent power |
| 07/28/2005 | US20050163851 Venlafaxine hydrocloride and sodium chloride; crystals of the sodium chloride are not coated with cellulose acetate butyrate; less conducive to producing drug-drug interactions between the first drug and venlafaxine; drug is not pseudoephedrine or oxybutynin |
| 07/28/2005 | US20050163850 Administration of levodopa and carbidopa |